Dolly A. Vance
2019
In 2019, Dolly A. Vance earned a total compensation of $1.2M as Executive Vice President, Corporate Affairs, General at Rigel Pharmaceuticals, a 33% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $239,288 |
|---|---|
| Option Awards | $420,682 |
| Salary | $514,598 |
| Other | $7,394 |
| Total | $1,181,962 |
Vance received $514.6K in salary, accounting for 44% of the total pay in 2019.
Vance also received $239.3K in non-equity incentive plan, $420.7K in option awards and $7.4K in other compensation.
Rankings
In 2019, Dolly A. Vance's compensation ranked 8,503rd out of 13,971 executives tracked by ExecPay. In other words, Vance earned more than 39.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,503 out of 13,971 | 39th |
Division Manufacturing | 3,369 out of 5,701 | 41st |
Major group Chemicals And Allied Products | 1,275 out of 2,200 | 42nd |
Industry group Drugs | 1,085 out of 1,886 | 43rd |
Industry Pharmaceutical Preparations | 805 out of 1,398 | 42nd |
Source: SEC filing on April 1, 2020.
Vance's colleagues
We found six more compensation records of executives who worked with Dolly A. Vance at Rigel Pharmaceuticals in 2019.
2019
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
2019
Anne-Marie Duliege
Rigel Pharmaceuticals
Chief Medical Officer
2019
Dean Schorno
Rigel Pharmaceuticals
Chief Financial Officer
2019
Eldon Mayer
Rigel Pharmaceuticals
Executive Vice President, Chief Commercial Officer
2019
Esteban Masuda
Rigel Pharmaceuticals
Executive Vice President, Research
2019
Wolfgang Dummer
Rigel Pharmaceuticals